immunocore-logo-2018
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable...
immunocore-logo-2018
Immunocore to present at the 21st Annual Needham Healthcare Conference
April 07, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 21st Annual Needham Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 7 April 2022) Immunocore Holdings Plc (Nasdaq: IMCR),...
immunocore-logo-2018
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
April 04, 2022 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to...
immunocore-logo-2018
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
March 09, 2022 17:30 ET | Immunocore Holdings Limited
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq:...
immunocore-logo-2018
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
March 03, 2022 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic...
immunocore-logo-2018
Immunocore to present at the SVB Leerink Global Healthcare Conference
February 11, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the SVB Leerink Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq:...
immunocore-logo-2018
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
December 06, 2021 07:00 ET | Immunocore Holdings Limited
         Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable...
immunocore-logo-2018
Immunocore to present at the Jefferies London Healthcare Conference
November 11, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq:...
immunocore-logo-2018
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions...
immunocore-logo-2018
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
September 08, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma MHRA’s...